Roar Dyrkorn
Papers
1
Total Citations
50
H-Index
1
About
Roar Dyrkorn is a leading figure in clinical pharmacology and bioanalytical chemistry, with a primary focus on the therapeutic drug monitoring of direct oral anticoagulants (DOACs). His most cited work, a 2018 study on the quantification of apixaban, dabigatran, edoxaban, and rivaroxaban in human serum, has garnered 50 citations. In this landmark paper, Dyrkorn and his team developed and validated a robust UHPLC-MS/MS method, addressing a critical clinical need: while DOACs are typically prescribed at fixed doses, measuring serum drug concentrations can be essential for managing patients with renal impairment, extreme body weight, or those requiring urgent surgery. By providing a reliable, sensitive, and specific analytical tool, Dyrkorn’s research enables clinicians to make informed dose adjustments, thereby improving patient safety and treatment efficacy. His work bridges the gap between complex bioanalytical method development and real-world clinical application, underscoring his impact on personalized anticoagulation therapy. Dyrkorn’s contributions are vital for advancing precision medicine in thrombosis management.
Research Focus
Key Achievements
Top Papers
- 1